Recombinant Human MRC2 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2653

---

Validation Data Gallery

• 

  Purity of Recombinant Human MRC2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human MRC2 protein Gly31-Ala1414 (Accession# Q9UBG0) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 9902
• Accession: Q9UBG0
• PredictedSize: 182.1 kDa
• SDS-PAGE: 150-200 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

C-type mannose receptor 2 (MRC2), also known as CD280, CLEC13E, ENDO180, KIAA0709, or UPARAP, is a type I transmembrane glycoprotein that belongs to the macrophage mannose receptor protein family. It contains an N-terminal cysteine-rich domain, a fibronectin type II domain (FNII), eight C-type-lectin-like domains, and a transmembrane region followed by a small cytoplasmic domain. MRC2 is a recycling endocytic receptor that functions in both these cellular activities by promoting cell migration and uptake of collagens for intracellular degradation. MRC2 is expressed in several cells and organs including fibroblasts, endothelial cells, and macrophages. Altered MRC2 expression has been associated with the development and progression of different cancers, including head and neck squamous cell carcinoma, breast cancer, hepatocellular cancer, and prostate cancer.

References:

1.Sheikh H, et al. (2000) J Cell Sci. 113 ( Pt 6):1021-32.
2.Behrendt N, et al. (2000) J Biol Chem. 275(3):1993-2002.
3.Ishikawa K, et al. (1998) DNA Res. 5(3):169-76.
4.Li L, et al. (2021) Anal Cell Pathol (Amst). 2021:6619870.
5.Wienke D, et al. (2007) Cancer Res. 67(21):10230-40.
6.Zhao Z, et al. (2022) Front Mol Biosci. 9:951636.
7.Gopalakrishnan KV, et al. (2023) J Stomatol Oral Maxillofac Surg. 124(6S):101617.
8.Gai X, et al. (2014) Int J Mol Sci. 15(9):15011-25.